Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

NCT01280565 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

134

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on portfolio prioritization

Conditions

Metastatic Melanoma

Interventions

DRUG: Masitinib
DRUG: Dacarbazine

Sponsor

AB Science